Abbott has taken a step forward in the development of a new addition to its structural heart portfolio, completing the first ...

Boston Scientific has signed a deal to acquire the maker of a chemotherapy infusion pump aimed at treating certain inoperable ...

Advantage Therapeutics is spinning off some of its age-related disease R&D into a new company called Klothea Bio. | Klothea ...

A phase 3 trial of Biohaven’s taldefgrobep alfa in spinal muscular atrophy (SMA) has missed its primary endpoint. The biotech ...

HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

The annual Fierce 50 Gala is set to shine a spotlight on the life sciences industry's most transformative leaders, ...

Adcendo is adding $135 million to its arsenal, money that will go toward launching several antibody-drug conjugate (ADC) ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

To recruit volunteers more quickly for clinical trials, a team of National Institutes of Health (NIH) researchers has turned ...